Alvotech - (ALVO) closed at $4.48 on November 2, 2026, down 3.7% from the previous close, on volume of 1,495,629 shares (30-day average 941,695).
Data as of November 2, 2026.
Alvotech to Present at Upcoming Investor Conferences in November
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Globe Newswire (Wed, 28-Oct 7:00 AM ET)
Alvotech Wins FDA Nod for SIMLANDI Process 2.0 That More Than Doubles Output Per Batch
Market Chameleon (Tue, 20-Oct 3:07 AM ET)
Globe Newswire (Tue, 20-Oct 4:30 AM ET)
Globe Newswire (Wed, 14-Oct 4:30 AM ET)
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Globe Newswire (Tue, 6-Oct 4:36 PM ET)
ALVO Rallies After FDA Clears a Second Reykjavik Suite for SIMLANDI U.S. Supply
Market Chameleon (Mon, 5-Oct 6:30 AM ET)
Market Chameleon (Mon, 5-Oct 3:07 AM ET)
FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira
Globe Newswire (Mon, 5-Oct 4:00 AM ET)
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Alvotech - trades on the NASDAQ stock market under the symbol ALVO.
As of November 2, 2026, ALVO stock price declined to $4.48 with 1,495,629 million shares trading.
ALVO has a beta of 1.16, meaning it tends to be more sensitive to market movements. ALVO has a correlation of 0.04 to the broad based SPY ETF.
ALVO has a market cap of $1.52 billion. This is considered a Small Cap stock.
Last quarter Alvotech - reported $106 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $545,824 and missed earnings estimates by -$.09.
In the last 3 years, ALVO traded as high as $18.00 and as low as $2.94.
The top ETF exchange traded funds that ALVO belongs to (by Net Assets): IBB, IDNA, EWX, PRFZ, IBBQ.
ALVO has underperformed the market in the last year with a price return of -42.9% while the SPY ETF gained +11.7%. However, in the short term, ALVO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +25.5% vs +1.7% return in SPY. But in the last 2 weeks, ALVO shares have been beat by the market, returning -10.4% compared to an SPY return of -1.5%.
ALVO support price is $4.45 and resistance is $4.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALVO shares will trade within this expected range on the day.
